SSRIs are the most prescribed psychotropics in the world, and the place where most modern psychiatric pharmacology begins. Six agents — fluoxetine, sertraline, escitalopram, citalopram, paroxetine, fluvoxamine — share a single mechanism. They all block the same protein. They differ in half-life, metabolism, and side effect profile. Once you understand the shared mechanism, the differences between them stop being arbitrary and start being clinically useful.
- Class
- Selective Serotonin Reuptake Inhibitors
- Mechanism
- Block presynaptic serotonin reuptake transporter (SERT); raises synaptic serotonin → slow downstream plasticity over 4-8 weeks
- Typical dose
- Class-dependent (see specific drug cards)
- Half-life
- Class-dependent (fluoxetine longest ~4-6d, paroxetine shortest ~21h)
- FDA indications
- MDD, anxiety disorders, OCD, PTSD, PMDD, panic disorder, bulimia
- Key adverse effects
- GI (early, transient), sexual dysfunction (30-70%), discontinuation syndrome (short-acting agents), serotonin syndrome (combinations)
- Representative agents
- Fluoxetine, sertraline, escitalopram, citalopram, paroxetine, fluvoxamine
Black box: Suicidal thinking/behavior in pediatric and young adult patients
The mechanism is simple to state. Serotonin is released into the synapse. The presynaptic neuron has a transporter — the serotonin reuptake transporter, or SERT — whose job is to vacuum serotonin back up so it can be repackaged and released again. An SSRI binds SERT and blocks it. Serotonin sits in the cleft longer. Postsynaptic 5-HT receptors get more signal.
That happens on day one. The patient does not feel better on day one.
The discordance between when the synapse changes and when the patient changes is the central mystery of antidepressant pharmacology, and the most clinically important fact about SSRIs. If you understand only one thing about this class, understand this: synaptic onset is hours, therapeutic onset is weeks. Patients who do not understand this stop the medication on day three because of side effects and because it is "not working." Counsel them in advance.
Here is what happens during those weeks. After the synaptic serotonin rises, presynaptic 5-HT1A autoreceptors — which act as a brake, sensing how much serotonin is in the cleft and slowing release — start downregulating. The brake comes off. Sustained serotonergic signaling begins. Downstream, hippocampal neurogenesis increases. Default mode network connectivity normalizes. Prefrontal-amygdala plasticity remodels. The patient's circuits, over four to eight weeks, are doing the actual work.
The SSRI class translates a single molecular action — SERT blockade — into a wide clinical footprint. The mechanism-to-effect map explains both the shared class properties and where the timeline traps patients.
Mechanism note: The central clinical fact of the class is the discordance between synaptic onset (hours) and therapeutic onset (weeks). Solve the timing conversation at the first visit and you prevent most premature discontinuations.
The medication is the trigger. The brain is the engine.
Clinically, this is why an adequate trial is six to eight weeks at a therapeutic dose, not two weeks at a starter dose. Many "treatment-resistant" patients turn out to have failed a series of inadequate trials. Take a careful prior-medication history; ask what dose, for how long, with what response. The medication that "didn't work" often wasn't given a fair chance.
The differences within the class — fluoxetine's long half-life, paroxetine's anticholinergic burden, escitalopram's clean profile, sertraline's broad indications, citalopram's QTc concern, fluvoxamine's CYP interactions — are the texture you'll learn one concept at a time. The shared truth is the mechanism, and the shared trap is patient expectations about timing. Solve the timing conversation at the first visit, and you've saved yourself half the second-visit conversation.